Finasteride Market: How Hair Loss and Prostate Care Shape Product and Application Demand

Demand for finasteride is tied to two very different patient needs: hair care and prostate health. For manufacturers, distributors, and pharmacy chains, understanding how those needs shape product and application mix is central to reading the Finasteride Market. This article draws on the Polaris Market Research report to outline demand drivers, dosage segments, and competitive structure.

Market Snapshot

Polaris Market Research valued the global Finasteride Market at USD 106.06 million in 2025, with a 2026 estimate of USD 108.64 million. It is projected to reach USD 135.98 million by 2034, growing at a CAGR of 2.8% from 2026 to 2034. North America was the largest regional market in 2025.

Hair Loss Demand Across Regions

The rising demand for finasteride is highly influenced by the large number of people suffering from hair loss, which is becoming a significant source of psychological distress among males and females. Approximately two-thirds of men are expected to witness hair loss symptoms by the age of 35. The growing number of companies developing superior hair loss treatment medications, specifically for men, is anticipated to create significant demand potential for finasteride.

Recent activity reflects that momentum. In November 2023, HanAll Biopharma announced that monthly sales of its 1mg finasteride hair loss pills passed one million. Regionally, North America's lead is attributed to the rising number of men suffering from androgenic alopecia and to established players engaged in finasteride production. In Asia Pacific, Polaris expects rapid growth, citing healthcare investment and rising penetration of hair loss and prostate enlargement among men. It also cites Traya's 2023 finding that approximately 50.31% of Indian men under 25 face hair loss problems.

Dosage Segments

By product, the report splits the market into two dosage strengths. The lower strength is expected to post the highest CAGR during the projected period, driven by the rising number of people suffering from hair loss. 1mg finasteride is mostly used for hair loss among men, and Polaris links demand to societal perception and professional image as more people opt for hair care treatments.

5mg finasteride led the market with a substantial market size in 2023, largely because of its effective treatment of prostatic hyperplasia. The growing prevalence of the disease is likely to boost demand, and the product is approved by the US Food and Drug Administration for benign prostatic hyperplasia.

Prostate Applications Lead

By application, prostate treatment garnered the largest market share in 2025 and is likely to retain its position throughout the forecast period, reflecting finasteride's rising utility in prostate treatment over hair loss. Within it, the prostate enlargement sub-segment received the highest growth because of finasteride's performance in treating the enlargement that causes difficulty in urination among males.

The prostate cancer segment is projected to grow at a healthy rate, driven by the increased risk of prostate cancer among patients with benign prostatic enlargement. Polaris also cites a clinical study in which the finasteride group registered a 25% relative decrease in overall prostate cancer risk, from 24% to 18%.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :

https://www.polarismarketresearch.com/industry-analysis/finasteride-market 

Restraining Factors

Two factors temper growth. First, prominent substitutes and alternatives to finasteride in hair loss and benign prostatic hyperplasia applications are expected to restrain the market. Second, ongoing studies of side effects from oral finasteride pills, together with greater awareness of medicinal ingredients and improved internet availability, are anticipated to lower demand. Based on clinical trials, adverse effects include decreased libido, rash, ejaculation issues, and erectile dysfunction.

Key Players and Competitive Structure

Polaris describes the Finasteride Market as fairly consolidated, with a few larger players holding large revenue. Major players include Accord Pharmaceuticals (UK); Teva Pharmaceutical Industries Ltd.; Cipla (India); Merck (Germany); Mylan N.V. (US); RelonChem (UK); Sandoz (Switzerland); Topfond Pharmaceutical Co., Ltd.; Dr. Reddy's Laboratories (UK) Ltd.; and Novartis AG. Growing patent agreements, collaborations, and partnerships are expected to bolster market expansion.

For B2B teams, the picture is of a mature product whose demand rests on clearly defined clinical uses, balanced against side-effect awareness and alternative therapies. The full Polaris report offers deeper segment, regional, and company analysis.

Conclusion

The Finasteride Market is expected to demonstrate sustained demand, supported by the prevalence of androgenetic alopecia and benign prostatic hyperplasia. Increasing awareness regarding available treatment options is contributing to market development. The growing availability of generic formulations is improving affordability and accessibility across healthcare systems. Additionally, online pharmacy services and telehealth consultations are expanding access to prescription-based treatment. Manufacturers are exploring alternative formulations and delivery methods to improve treatment convenience and tolerability. Overall, the market outlook remains positive, although safety considerations, prescription requirements, and competition from alternative therapies will continue to influence adoption.

More Trending Latest Reports By Polaris Market Research:

Plastic Pallets Market

Europe Rare Disease Diagnostics Market

Digital Health Market

T4 DNA Ligase Market

Europe Rare Disease Diagnostics Market

Muscle Stimulator Market

Organic Rankine Cycle Market

Industrial IoT (IIoT) is bringing Transformation across Industries Worldwide

E-Commerce Market